Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine-Assisted Psychotherapy in Cancer-Related Distress
NCT05344625Phase 1Withdrawn
- Sponsor
- Northwell Health
- Start
- Oct 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ketamine in anxiety disorder and major depressive disorder (MDD), sponsored by Northwell Health. Primary endpoint: Percentage of population completing at least one KAP session. Planned start Oct 2023; status: withdrawn.
02
Drugs
ketamine
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05344625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05344625.